Pauwels P J, Colpaert F C
Centre de Recherche Pierre Fabre, Department of Cellular and Molecular Biology, 17, avenue Jean Moulin, 81106 Castres Cédex, France.
Neuropharmacology. 2000 Aug 23;39(11):2101-11. doi: 10.1016/s0028-3908(00)00040-x.
Ligand:receptor interactions were analysed at wild-type, Asp(79)Asn and Thr(373)Lys alpha(2A) AR by measuring Ca(++) responses in the co-presence of a G(alpha 15) protein in CHO-K1 cells. (-)-Adrenaline displayed a time-dependent Ca(++) response with the following magnitude: wt alpha(2A) AR>Thr(373)Lys alpha(2A) AR>Asp(79)Asn alpha(2A) AR. The maximal amplitude of activation by d-medetomidine and clonidine versus that of (-)-adrenaline was not affected by the Asp(79)Asn mutation, whereas it was significantly lower for both UK 14304 (-42%) and oxymetazoline (-35%). BHT 920 induced a higher Ca(++) response (+19%) at the Asp(79)Asn alpha(2A) AR. Some (atipamezole>BRL 44408=idazoxan approximately SKF 86466>dexefaroxan) but not all (RX 811059 and RS 15385) of the putative alpha(2) AR antagonists tested also displayed partial agonist properties at the Asp(79)Asn alpha(2A) AR. At the Thr(373)Lys alpha(2A) AR, high-efficacy responses were produced by each of the agonists, whereas the putative antagonists showed the following rank order of maximal responses: BRL 44408>SKF 86466>atipamezole approximately idazoxan>dexefaroxan. The observed heterogeneity of Ca(++) responses produced by different ligands at wt and mutant alpha(2A) AR may be explained by assuming the existence of multiple ligand activation binding sites at the alpha(2A) AR.
通过在CHO - K1细胞中共同存在G(α15)蛋白时测量Ca(++)反应,分析了野生型、天冬氨酸(79)→天冬酰胺和苏氨酸(373)→赖氨酸α(2A)肾上腺素能受体(AR)上的配体与受体相互作用。(-)-肾上腺素呈现出时间依赖性的Ca(++)反应,其幅度如下:野生型α(2A) AR>苏氨酸(373)→赖氨酸α(2A) AR>天冬氨酸(79)→天冬酰胺α(2A) AR。右美托咪定和可乐定相对于(-)-肾上腺素的最大激活幅度不受天冬氨酸(79)→天冬酰胺突变的影响,而对于UK 14304(-42%)和羟甲唑啉(-35%)两者而言均显著更低。BHT 920在天冬氨酸(79)→天冬酰胺α(2A) AR上诱导出更高的Ca(++)反应(+19%)。所测试的一些假定的α(2) AR拮抗剂(阿替美唑>BRL 44408 = 伊达唑安≈SKF 86466>右啡烷)但并非全部(RX 811059和RS 15385)在天冬氨酸(79)→天冬酰胺α(2A) AR上也表现出部分激动剂特性。在苏氨酸(373)→赖氨酸α(2A) AR上,每种激动剂均产生高效反应,而假定的拮抗剂显示出以下最大反应的排序:BRL 44408>SKF 86466>阿替美唑≈伊达唑安>右啡烷。不同配体在野生型和突变型α(2A) AR上产生的Ca(++)反应所观察到的异质性,可能通过假定在α(2A) AR上存在多个配体激活结合位点来解释。